Ascelia Pharma (Sweden) Performance
| ACE Stock | SEK 3.14 0.01 0.32% |
Ascelia Pharma has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Ascelia Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascelia Pharma is expected to be smaller as well. Ascelia Pharma AB right now shows a risk of 3.48%. Please confirm Ascelia Pharma AB semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to decide if Ascelia Pharma AB will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ascelia Pharma AB are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable technical and fundamental indicators, Ascelia Pharma is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
| Begin Period Cash Flow | 184.7 M | |
| Total Cashflows From Investing Activities | -38 K |
Ascelia |
Ascelia Pharma Relative Risk vs. Return Landscape
If you would invest 310.00 in Ascelia Pharma AB on December 18, 2024 and sell it today you would earn a total of 4.00 from holding Ascelia Pharma AB or generate 1.29% return on investment over 90 days. Ascelia Pharma AB is generating 0.0801% of daily returns assuming 3.4769% volatility of returns over the 90 days investment horizon. Simply put, 31% of all stocks have less volatile historical return distribution than Ascelia Pharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Ascelia Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascelia Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ascelia Pharma AB, and traders can use it to determine the average amount a Ascelia Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ACE | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.48 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Ascelia Pharma is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascelia Pharma by adding it to a well-diversified portfolio.
Ascelia Pharma Fundamentals Growth
Ascelia Stock prices reflect investors' perceptions of the future prospects and financial health of Ascelia Pharma, and Ascelia Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascelia Stock performance.
| Return On Equity | -0.54 | |||
| Return On Asset | -0.33 | |||
| Current Valuation | 359.6 M | |||
| Shares Outstanding | 33.67 M | |||
| Price To Book | 2.34 X | |||
| EBITDA | (129.45 M) | |||
| Cash And Equivalents | 219.15 M | |||
| Cash Per Share | 9.69 X | |||
| Total Debt | 553 K | |||
| Book Value Per Share | 5.19 X | |||
| Cash Flow From Operations | (116.56 M) | |||
| Earnings Per Share | (3.67) X | |||
| Total Asset | 333.49 M | |||
About Ascelia Pharma Performance
Assessing Ascelia Pharma's fundamental ratios provides investors with valuable insights into Ascelia Pharma's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Ascelia Pharma is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Ascelia Pharma AB operates as an oncology focused specialty pharmaceutical company that develops medicines to enhance the life expectancy for people living with cancer and cancer-related diseases in Sweden and Denmark. The company was founded in 2000 and is headquartered in Malm, Sweden. Ascelia Pharma operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 4 people.Things to note about Ascelia Pharma AB performance evaluation
Checking the ongoing alerts about Ascelia Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascelia Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ascelia Pharma AB had very high historical volatility over the last 90 days | |
| Ascelia Pharma AB has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (125.9 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Ascelia Pharma AB has accumulated about 219.15 M in cash with (116.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 23.0% of the company shares are held by company insiders |
- Analyzing Ascelia Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascelia Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascelia Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascelia Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascelia Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascelia Pharma's stock. These opinions can provide insight into Ascelia Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Ascelia Stock Analysis
When running Ascelia Pharma's price analysis, check to measure Ascelia Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascelia Pharma is operating at the current time. Most of Ascelia Pharma's value examination focuses on studying past and present price action to predict the probability of Ascelia Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascelia Pharma's price. Additionally, you may evaluate how the addition of Ascelia Pharma to your portfolios can decrease your overall portfolio volatility.